1. India Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Genomic Valley Biotech Ltd

Genomic Valley Biotech Ltd

BBSE:GVBL
37.71
INR
+1.79
(+4.98%)
0.13EPS
228.28P/E
88.43MMarket Cap
Genomic Valley Biotech Ltd
BSE:GVBL
(Bombay Stock Exchange)

Recent

price

37.71

P/E

ratio

228.28

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
0.11
0.36
1.42
1.92
3.22
2.78
0.68
0.23
8.9
0.54
2.77
0.88
0.69
Revenue per Share
-0.03
-1.1
-0.22
0.11
0.76
0.94
-1.83
-0.03
2.12
0.05
1.17
0.1
0.13
Basic EPS, GAAP
-0.16
-2.52
-0.49
2.82
-3.39
1.44
4.86
-6.84
-2.55
-0.07
0.09
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
16.03
14.94
14.71
14.83
15.59
16.52
14.69
9.42
11.55
11.6
12.76
12.86
- -
Book Value per Share
16.03
14.94
14.71
14.83
15.59
16.47
14.65
9.4
11.55
11.6
12.76
12.86
- -
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
- -
1
4
6
10
8
2
1
27
2
8
3
2
Sales/Revenue/Turnover
-11.55
-450.33
-32.92
4.75
23.9
45.71
-147.55
-572.23
32.09
9.99
51.78
14.97
23.83
Operating Margin (%)
- -
1
- -
1
2
2
2
1
- -
- -
- -
- -
- -
Depreciation Expense
- -
-3
-1
- -
2
3
-6
- -
6
- -
4
- -
- -
Net Income, GAAP
- -
- -
- -
41.81
0.94
- -
- -
- -
0.09
- -
19.33
24.32
18.96
Effective Tax Rate (%)
-27.76
-307.08
-15.54
5.73
23.6
33.78
-268.67
-13.24
23.81
9.2
42.19
11.33
19.31
Profit Margin (%)
19
-5
-6
-13
2
-4
-7
9
17
21
22
24
- -
Working Capital
8
8
8
8
15
15
15
- -
- -
- -
- -
- -
- -
LT Debt
49
46
45
45
48
50
45
29
35
35
39
39
- -
Total Equity
- -
- -
- -
0.52
4.05
- -
- -
- -
18.51
- -
9.33
0.76
- -
Return on Invested Capital (%)
- -
- -
- -
0.65
4.04
- -
- -
- -
20.25
- -
9.57
0.77
- -
Return on Capital (%)
- -
-7.08
-1.51
0.76
5.01
5.83
-11.73
-0.25
20.24
0.43
9.57
0.77
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
3
3
Market Capitalization
87
86
88

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
27
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
23
- -
Inventories
- -
3
- -
Total Current Liabilities
- -
3
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.28%
-0.42%
0.78%
Free Cash Flow
-168.52%
-161.76%
-170.75%
Net Income, GAAP
-500.21%
-1,016.48%
-91.49%
Sales/Revenue/Turnover
425.68%
788.23%
-68.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2
2
2
3
8
2026
1
- -
1
- -
3
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.42
0.48
0.51
-0.27
1.17
2026
0.08
- -
0.03
-0.03
0.1
2027
0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Genomic Valley Biotech Ltd. (Ticker: GVBL.BO) is a biotechnology company specializing in the development, manufacturing, and commercialization of genomic and biotechnological products and services. The company's core offerings include advanced genomic sequencing technologies, molecular diagnostics, custom genetic testing services, gene editing solutions, bioinformatics software, and research reagents. Genomic Valley Biotech serves pharmaceutical companies, research institutions, healthcare providers, and agricultural biotech firms with a focus on precision medicine and life sciences innovation. Founded in 2010 and headquartered in India, Genomic Valley Biotech operates primarily in India with expanding geographic reach into global markets through collaborations and partnerships. In the last 1 to 2 years, the company has strengthened its strategic position by entering new alliances for technology integration and expanding its service portfolio with novel genomic assays. It has also launched new product lines targeting personalized medicine and agricultural genomics sectors while enhancing its bioinformatics capabilities. Operational and organizational improvements have been implemented to support scaling efforts and global service delivery. The company is positioned in the biotechnology and genomics industry, targeting research organizations and commercial clients across healthcare, pharmaceuticals, and agriculture. It maintains a robust portfolio aligned with current trends in genomic medicine, molecular diagnostics, and biotech innovation, underscoring its commitment to scientific advancement and market growth. Genomic Valley Biotech continues to evolve through technology upgrades, strategic partnerships, and expanded service offerings to solidify its market presence in India and internationally.